| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2964 | Ks-133 | Novel Potent and Selective VIPR2 Antagonist, Counteracting Cognitive Decline in a Mouse Model of Psychiatric Disorders |
|
| DCC2965 | Ksc-392-150 | Novel inhibitor of the permeability transition pore (PTP) |
|
| DCC2966 | kscm-1 | Selective ligand of the sigma-1 receptor |
|
| DCC2967 | Kscm-11 | Ligand of the sigma receptor |
|
| DCC2968 | kscm-5 | Ligand of the sigma receptor |
|
| DCC2969 | Ksk120 | Novel inhibitor of transcriptional activity in Chlamydia trachomatis |
|
| DCC2970 | Ksl-128114 | Novel, highly potent, and metabolically stable peptide inhibitor of syntenin, Inhibiting Glioblastoma |
|
| DCC2971 | Kspa-1 | Novel modulator of kinesin spindle protein (KSP)/Eg5, activating KSP-catalyzed ATP hydrolysis in the absence of microtubules yet inhibiting microtubule-stimulated ATP hydrolysis by KSP |
|
| DCC2972 | Kt-182 | Potent and selective inhibitor of ABHD6 |
|
| DCC2973 | Kt2-962 | TXA2/prostaglandin endoperoxide receptor antagonist |
|
| DCC2974 | Kta-439 | Thyroid hormone receptor β (TRβ) selective agonist |
|
| DCC2975 | Ku-2285 | Hypoxic cell radiosensitizer |
|
| DCC2976 | Kufal194 | Novel selective DYRK1A inhibitor |
|
| DCC2977 | Kunb31 | Novel potent and selective inhibitor of Hsp90β |
|
| DCC2978 | Kurasoin B | Novel protein farnesyltransferase inhibitor |
|
| DCC2979 | kv1.5-in-iiii | Potent Kv1.5 inhibitor |
|
| DCC2980 | Kv2.1/syntaxin-in-cpd5 | Novel neuroprotectant, inhibiting Kv2.1-syntaxin molecular interaction |
|
| DCC2981 | Kva-d-88 | Novel Preferable Phosphodiesterase 4B (PDE4B) Inhibitor, Decreasing Cocaine-Mediated Reward Properties in Vivo |
|
| DCC2982 | Ky1022 | Ras destabilizer, targeting the Wnt/ß-catenin pathway and inhibiting development of metastatic colorectal cancer |
|
| DCC2983 | Kya1797 | Novel inhibitor of the Wnt/ß-catenin pathway, binding directly to the regulators of G-protein signaling domain of axin, initiating ß-catenin and Ras degradation through enhancement of the ß-catenin destruction complex activating GSK3ß, effectively suppres |
|
| DCC2984 | Kys05047 | Selective T-type Ca(2+) channel blocker with anti-proliferative effects against various cancer cells |
|
| DCC2985 | L-161240 | Potent inhibitor of LpxC and lipid A biosynthesis |
|
| DCC2986 | L-162782 | Nonpeptide agonist of angiotensin AT1 receptor |
|
| DCC2987 | L17er4 | Novel cell-permeable attenuated cationic amphiphilic lytic (ACAL) peptide, efficiently bring immunoglobulin G (IgG) and other functional proteins into cells |
|
| DCC2988 | L2-4048 | Novel Migration Inhibitory Factor (MIF) inhibitor, binding at the allosteric and tautomerase sites, blocking MIF's tautomerase CD74 receptor binding, and pro-inflammatory activities |
|
| DCC2989 | L458-bpyne | Novel γ-secretase modulator photoaffinity probe, identifying distinct allosteric binding sites on presenilin that can be exploited to reduce levels of pathogenic Aβ species |
|
| DCC2990 | L465046 (α-synuclein Amyloid Aggregation Inhibitor) | Novel inhibitor of α-synuclein amyloid aggregation for the treatment of Parkinson's disease |
|
| DCC2991 | L524-0366 | Novel inhibitor of the TWEAK-Fn14 signaling cascade |
|
| DCC2992 | L61h46 | Novel potent inhibitor of human pancreatic cancer cells |
|
| DCC2993 | L-651392 | Potent leukotriene inhibitor |
|
